Answers are grounded in this paper and cite their sources.
Randomized trial assesses cognitive improvement in stroke patients, suggesting effective treatment options for cognitive disorders.
Background and aims Cognitive disorders (CD) is a significant cause of disability and limitation of capabilities in people who have suffered a stroke. Methods 93 patients aged 54.7 ± 14.8 years who had suffered a stroke were examined. All patients underwent neurological examination, neuropsychological testing, and neuroimaging. Depending on the severity and prevalence of CD, patients were divided into groups: group 1 (n=21) - with focal disorders, group 2 (n=25) - with multiple CD, without dementia; group 3 (n=27) - with post-stroke dementia; group 4 (n=20) - control. Results In each group, patients with early and late CD were identified. The main causes of CD in group 1 were patients with ischemic 65% and 35% with hemorrhagic strokes, in group 2 – ischemic 39%, massive hemorrhagic 61%, in group 3 – multiple lacunar infarctions 46%, hemorrhages 54%. Patients were prescribed treatment with citicoline at a dose of 1000 mg per day, group 2 was added amantadine at a dose of 100 mg twice a day, group 3 – amantadine 100 mg twice a day and donepezil at a dose of 5 mg per day. The course of treatment was 3 months. During the treatment, changes occurred: on the Mokka scale in group 1 21.7±1.3 versus 19.2±1.8 before treatment; group 2 - 24.2±1.1 vs. 18.2±0.9 before treatment (p<0.05); group 3 - 23.3±0.6 vs. 16.7±0.5 (p<0.05), respectively. Conclusions The risk of developing post-stroke CD does not depend on the nature and severity of the stroke; citicoline, amantadine, and cholinesterase inhibitors in treatment regimens have a positive effect on CD. Conflict of interest KateynaTarianyk: nothing to disclose; Nazarii Kalynovych: nothing to disclose
No takes yet. Share an insight, caveat, or question.
Tarianyk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: